NewGenIVF to execute $2 million share repurchase via Benchmark

NewGenIVF Group Limited (NASDAQ: NIVF) announced it will execute a previously authorized share repurchase program of up to $2 million through The Benchmark Company, LLC, a subsidiary of StoneX Group Inc.

The Bangkok-based company's board of directors authorized the share repurchase program on November 10, 2025. The program allows NewGenIVF to repurchase shares through open market purchases or other permitted methods, subject to market conditions, share price, and trading volume.

Benchmark will handle execution and operational aspects of trades under the program in accordance with regulatory requirements. The company expects to utilize Benchmark's institutional trading platform and execution capabilities.

"We continue to believe that the market does not fully recognize the value of our business, the progress we have made, or the scale of opportunities ahead of us," said Siu Wing Fung Alfred, founder, chairman, and CEO of NewGenIVF.

NewGenIVF operates across three business divisions: NewGenProperty for real estate development in the UAE's Ras Al Khaimah Emirate, NewGenDigital for digital asset and DeFi solutions, and NewGenSup for health and longevity products. The company also provides IVF and assisted reproductive treatment services across Asia.

The repurchase program does not obligate the company to repurchase any specific number of shares and may be modified, suspended, or terminated at any time. The company stated that management believes its current market valuation does not fully reflect underlying business fundamentals and long-term strategic potential.

You May Also Be Interested In